Gemma M. Ryan

发表

Liposomal Formulations to Modulate the Tumour Microenvironment and Antitumour Immune Response

M. Bally, K. Bennewith, Roger Gilabert-Oriol, 2018, International journal of molecular sciences.

Nano-chemotherapeutics: maximising lymphatic drug exposure to improve the treatment of lymph-metastatic cancers.

Christopher J. H. Porter, C. Porter, Lisa M. Kaminskas, 2014, Journal of controlled release : official journal of the Controlled Release Society.

Pulmonary administration of a doxorubicin-conjugated dendrimer enhances drug exposure to lung metastases and improves cancer therapy.

D. Owen, L. Kaminskas, B. Kelly, 2014, Journal of controlled release : official journal of the Controlled Release Society.

Methotrexate-conjugated PEGylated dendrimers show differential patterns of deposition and activity in tumor-burdened lymph nodes after intravenous and subcutaneous administration in rats.

D. Owen, D. Ascher, T. Velkov, 2015, Molecular pharmaceutics.

Lymphatic transport and lymph node targeting of methotrexate-conjugated PEGylated dendrimers are enhanced by reducing the length of the drug linker or masking interactions with the injection site.

D. Owen, L. Kaminskas, B. Kelly, 2017, Nanomedicine : nanotechnology, biology, and medicine.

Pulmonary administration of PEGylated polylysine dendrimers: absorption from the lung versus retention within the lung is highly size-dependent.

D. Owen, L. Kaminskas, B. Kelly, 2013, Molecular pharmaceutics.

Optimal PEGylation can improve the exposure of interferon in the lungs following pulmonary administration.

L. Kaminskas, Victoria M Mcleod, C. Porter, 2015, Journal of pharmaceutical sciences.

Copper (II) complexes of bidentate ligands exhibit potent anti-cancer activity regardless of platinum sensitivity status

M. Bally, M. Wehbe, C. Lo, 2017, Investigational New Drugs.

A Comparison of the Pharmacokinetics and Pulmonary Lymphatic Exposure of a Generation 4 PEGylated Dendrimer Following Intravenous and Aerosol Administration to Rats and Sheep

Victoria M Mcleod, C. Porter, P. Enkhbaatar, 2015, Pharmaceutical Research.

PEGylated polylysine dendrimers increase lymphatic exposure to doxorubicin when compared to PEGylated liposomal and solution formulations of doxorubicin.

Christopher J H Porter, Lisa M Kaminskas, D. Owen, 2013, Journal of controlled release : official journal of the Controlled Release Society.

DMPC/Chol liposomal copper CX5461 is therapeutically superior to a DSPC/Chol formulation.

M. Bally, M. Anantha, Gemma M. Ryan, 2022, Journal of controlled release : official journal of the Controlled Release Society.

Pulmonary administration of a doxorubicin-conjugated dendrimer enhances drug exposure to lung metastases and improves cancer therapy.

D. Owen, B. Kelly, Victoria M Mcleod, 2014, Journal of controlled release : official journal of the Controlled Release Society.

Methotrexate-conjugated PEGylated dendrimers show differential patterns of deposition and activity in tumor-burdened lymph nodes after intravenous and subcutaneous administration in rats.

D. Owen, D. Ascher, T. Velkov, 2015, Molecular pharmaceutics.